124 related articles for article (PubMed ID: 37634473)
1. A small molecule BCL6 inhibitor as chemosensitizers in acute myeloid leukemia.
Zhang L; Wu M; Guo W; Zhu S; Li S; Lv S; Li Y; Liu L; Xing Y; Chen H; Liu M; Peng S; Chen Y; Yi Z
Biomed Pharmacother; 2023 Oct; 166():115358. PubMed ID: 37634473
[TBL] [Abstract][Full Text] [Related]
2. BCL6 maintains survival and self-renewal of primary human acute myeloid leukemia cells.
Kawabata KC; Zong H; Meydan C; Wyman S; Wouters BJ; Sugita M; Goswami S; Albert M; Yip W; Roboz GJ; Chen Z; Delwel R; Carroll M; Mason CE; Melnick A; Guzman ML
Blood; 2021 Feb; 137(6):812-825. PubMed ID: 32911532
[TBL] [Abstract][Full Text] [Related]
3. In vitro activity of a G-quadruplex-stabilizing small molecule that synergizes with Navitoclax to induce cytotoxicity in acute myeloid leukemia cells.
Montoya JJ; Turnidge MA; Wai DH; Patel AR; Lee DW; Gokhale V; Hurley LH; Arceci RJ; Wetmore C; Azorsa DO
BMC Cancer; 2019 Dec; 19(1):1251. PubMed ID: 31881855
[TBL] [Abstract][Full Text] [Related]
4. Radotinib enhances cytarabine (Ara-C)-induced acute myeloid leukemia cell death.
Heo SK; Noh EK; Yu HM; Kim DK; Seo HJ; Lee YJ; Cheon J; Koh SJ; Min YJ; Choi Y; Jo JC
BMC Cancer; 2020 Dec; 20(1):1193. PubMed ID: 33276759
[TBL] [Abstract][Full Text] [Related]
5. Superior anti-tumor activity of the MDM2 antagonist idasanutlin and the Bcl-2 inhibitor venetoclax in p53 wild-type acute myeloid leukemia models.
Lehmann C; Friess T; Birzele F; Kiialainen A; Dangl M
J Hematol Oncol; 2016 Jun; 9(1):50. PubMed ID: 27353420
[TBL] [Abstract][Full Text] [Related]
6. Gilteritinib-induced upregulation of S100A9 is mediated through BCL6 in acute myeloid leukemia.
Zavorka Thomas ME; Jeon JY; Talebi Z; Buelow DR; Silvaroli J; Campbell MJ; Sparreboom A; Pabla N; Baker SD
Blood Adv; 2021 Dec; 5(23):5041-5046. PubMed ID: 34614509
[TBL] [Abstract][Full Text] [Related]
7. Cooperative effect of chidamide and chemotherapeutic drugs induce apoptosis by DNA damage accumulation and repair defects in acute myeloid leukemia stem and progenitor cells.
Li Y; Wang Y; Zhou Y; Li J; Chen K; Zhang L; Deng M; Deng S; Li P; Xu B
Clin Epigenetics; 2017; 9():83. PubMed ID: 28814980
[TBL] [Abstract][Full Text] [Related]
8. Artesunate reverses cytarabine resistance in acute myeloid leukemia by blocking the JAK/STAT3 signaling.
Su Q; Huang P; Luo X; Zhang P; Li H; Chen Y
Hematology; 2023 Dec; 28(1):2255802. PubMed ID: 37815490
[TBL] [Abstract][Full Text] [Related]
9. Obatoclax potentiates the cytotoxic effect of cytarabine on acute myeloid leukemia cells by enhancing DNA damage.
Xie C; Edwards H; Caldwell JT; Wang G; Taub JW; Ge Y
Mol Oncol; 2015 Feb; 9(2):409-21. PubMed ID: 25308513
[TBL] [Abstract][Full Text] [Related]
10. Human stem cell factor-antibody [anti-SCF] enhances chemotherapy cytotoxicity in human CD34+ resistant myeloid leukaemia cells.
Lu C; Hassan HT
Leuk Res; 2006 Mar; 30(3):296-302. PubMed ID: 16112192
[TBL] [Abstract][Full Text] [Related]
11. Stem cell factor as a survival and growth factor in human normal and malignant hematopoiesis.
Hassan HT; Zander A
Acta Haematol; 1996; 95(3-4):257-62. PubMed ID: 8677752
[TBL] [Abstract][Full Text] [Related]
12. Smac mimetic primes apoptosis-resistant acute myeloid leukaemia cells for cytarabine-induced cell death by triggering necroptosis.
Chromik J; Safferthal C; Serve H; Fulda S
Cancer Lett; 2014 Mar; 344(1):101-109. PubMed ID: 24184825
[TBL] [Abstract][Full Text] [Related]
13. Co-inhibition of HDAC and MLL-menin interaction targets MLL-rearranged acute myeloid leukemia cells via disruption of DNA damage checkpoint and DNA repair.
Ye J; Zha J; Shi Y; Li Y; Yuan D; Chen Q; Lin F; Fang Z; Yu Y; Dai Y; Xu B
Clin Epigenetics; 2019 Oct; 11(1):137. PubMed ID: 31590682
[TBL] [Abstract][Full Text] [Related]
14. Targeting the wee1 kinase for treatment of pediatric Down syndrome acute myeloid leukemia.
Caldwell JT; Edwards H; Buck SA; Ge Y; Taub JW
Pediatr Blood Cancer; 2014 Oct; 61(10):1767-73. PubMed ID: 24962331
[TBL] [Abstract][Full Text] [Related]
15. EIF4A inhibition targets bioenergetic homeostasis in AML MOLM-14 cells in vitro and in vivo and synergizes with cytarabine and venetoclax.
Fooks K; Galicia-Vazquez G; Gife V; Schcolnik-Cabrera A; Nouhi Z; Poon WWL; Luo V; Rys RN; Aloyz R; Orthwein A; Johnson NA; Hulea L; Mercier FE
J Exp Clin Cancer Res; 2022 Dec; 41(1):340. PubMed ID: 36482393
[TBL] [Abstract][Full Text] [Related]
16. Inhibition of MEK signaling enhances the ability of cytarabine to induce growth arrest and apoptosis of acute myelogenous leukemia cells.
Nishioka C; Ikezoe T; Yang J; Yokoyama A
Apoptosis; 2009 Sep; 14(9):1108-20. PubMed ID: 19548087
[TBL] [Abstract][Full Text] [Related]
17. Mechanisms responsible for the synergistic antileukemic interactions between ATR inhibition and cytarabine in acute myeloid leukemia cells.
Ma J; Li X; Su Y; Zhao J; Luedtke DA; Epshteyn V; Edwards H; Wang G; Wang Z; Chu R; Taub JW; Lin H; Wang Y; Ge Y
Sci Rep; 2017 Feb; 7():41950. PubMed ID: 28176818
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of arabinocytosine (AraC) toxicity to AML cells by a differentiation agent combination.
Wang X; Harrison JS; Studzinski GP
J Steroid Biochem Mol Biol; 2016 Nov; 164():72-78. PubMed ID: 26319201
[TBL] [Abstract][Full Text] [Related]
19. Therapeutic potential of GSK-J4, a histone demethylase KDM6B/JMJD3 inhibitor, for acute myeloid leukemia.
Li Y; Zhang M; Sheng M; Zhang P; Chen Z; Xing W; Bai J; Cheng T; Yang FC; Zhou Y
J Cancer Res Clin Oncol; 2018 Jun; 144(6):1065-1077. PubMed ID: 29594337
[TBL] [Abstract][Full Text] [Related]
20. Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis.
Liu N; Wang C; Wang L; Gao L; Cheng H; Tang G; Hu X; Wang J
Int J Mol Med; 2016 Jun; 37(6):1686-96. PubMed ID: 27082972
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]